The oil and gas exploration company reported Wednesday fourth-quarter earnings of $116.9 million, or $1.36 a share, slightly down from year-ago earnings of $117.6 million, or $1.37."We reiterate our Perform rating on the shares due to XEC's below-average production growth rate, estimated at 4-10% in 2012, and an oil/gas production mix that continues to be highly levered to gas. XEC does not have any gas hedges in 2012 or 2013, leaving it fully exposed to the current low gas price environment," Oppenheimer analysts wrote in a report Thursday. Shares of Cimarex Energy were upgraded to buy from hold by TheStreet Ratings. Cimarex has a forward P/E of 11.61; the average for exploration and production companies is 20.04. For comparison, Southwestern Energy (SWN) and Concho Resources (CXO) both have higher forward P/Es of 21.47 and 21.87, respectively. Thirteen of the 21 analysts who cover Cimarex rated it a buy; eight rated it a hold. Cimarex gets a B- grade from TheStreet Ratings with a $94.24 price target. The stock closed Thursday at $80.96 and has increased 30.79% year to date.
CareFusion The medical technology company earlier this month reported second-quarter earnings of $95 million, or 42 cents a share, up from year-ago earnings of $76 million, or 34 cents. "We estimate that in order to meet management's goal of 20%-plus operating margin exiting fiscal 2014, the company needs to reduce expenses by 3% from the fiscal 2011 base," Morgan Keegan analysts wrote in a report Friday. "Given the sheer number of cost reduction initiatives that are ongoing, we believe that management can meets its goals." Shares of CareFusion were upgraded to buy from hold by TheStreet Ratings. CareFusion has a forward P/E of 12.89; the average for medical equipment companies is 32.59. For comparison, Abiomed (ABMD) has a forward P/E of 121.79. Of the 16 analysts who cover CareFusion, nine rated it a buy and seven rated it a hold. TheStreet Ratings gives CareFusion a B grade with a $29.29 price target. The stock closed Thursday at $25.86 and has increased 1.77% year to date.
>To contact the writer of this article, click here: Alexandra Zendrian >To submit a news tip, send an email to: firstname.lastname@example.org. >To follow the writer on Twitter, go to Alexandra Zendrian.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV